Login to Your Account



Clinic Roundup


Tuesday, May 1, 2012
• Hemispherx Biopharma Inc., of Philadelphia, said Ampligen (rintatolimod), an experimental immunotherapeutic, was administered intranasally in conjunction with FluMist (influenza vaccine live, intranasal) to healthy volunteers in a study at the University of Alabama at Birmingham.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription